DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

BLA 103792/S-5344
BLA 125409/S-121
BLA 125427/S-102

SUPPLEMENT APPROVAL

Genentech, Inc.
Attention: Allison Guy, M.Sc., RAC
Regulatory Program Management
1 DNA Way
South San Francisco, CA 94080-4990

Dear Ms. Guy:

Please refer to your Supplemental Biologics License Applications (sBLA), dated April 6, 2018, and your amendments, submitted under section 351(a) of the Public Health Service Act for:

- BLA 103792/S-5344 Herceptin® (trastuzumab) for Injection, 150 mg lyophilized powder in a single-dose vial for reconstitution and 420 mg lyophilized powder in a multiple-dose vial for reconstitution
- BLA 125409/S-121 Perjeta® (pertuzumab) Injection, for intravenous use, 420 mg/14 mL single-dose vial
- BLA 125427/S-102 Kadcyla® (ado-trastuzumab emtansine) for Injection, for intravenous use, lyophilized powder in single-use vials containing 100 mg per vial or 160 mg per vial.

These Prior Approval Supplements (PAS) provide for the addition of language regarding tumor lysis syndrome (TLS) to the ADVERSE REACTIONS, Post-marketing Experience section of the Full Prescribing Information for all three products. The supplements were submitted in response to the agency's March 19, 2018, Supplement Request letter.

The Perjeta supplement also provides for the inclusion of angioedema under the existing WARNINGS AND PRECAUTIONS, Hypersensitivity Reactions/Anaphylaxis section (5.4) of the Perjeta prescribing information.

APPROVAL & LABELING

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at: http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling text for the Prescribing Information, and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Amy Tilley, Regulatory Project Manager, at 301-796-3994.

Sincerely,

{See appended electronic signature page}

Laleh Amiri-Kordestani, MD
Supervisory Associate Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

LALEH AMIRI KORDESTANI
09/20/2018